Common Side Effects Reported in Trials
Trametinib, a MEK inhibitor, shows side effects in colorectal cancer trials consistent with its mechanism of blocking the MAPK pathway. In phase 2 trials like those combining trametinib with other agents (e.g., cetuximab or irinotecan), patients experienced rash (up to 70%), diarrhea (50-60%), fatigue (40-50%), nausea (30-40%), and dermatitis acneiform (20-30%). These are typically grade 1-2 and manageable with dose adjustments.[1][2]
Serious Adverse Events
Higher-grade toxicities include skin infections (10-15%), ocular issues like retinal vein occlusion or blurred vision (5-10%), and cardiac events such as decreased ejection fraction (3-5%). In the NCI-MATCH trial (EAY131), trametinib monotherapy in BRAF-mutated colorectal cancer led to 20% of patients discontinuing due to toxicity, mainly rash, diarrhea, and fatigue.[3] Liver enzyme elevations and interstitial lung disease occur rarely but prompted trial halts in some cases.
Differences from Other Cancers
Side effects mirror those in melanoma trials but appear more frequent in colorectal cancer due to combo therapies and heavier pretreatment. A 2021 meta-analysis of GI cancer trials found higher rates of grade 3+ diarrhea (OR 2.5 vs. monotherapy) when paired with EGFR inhibitors.[4]
Patient Management and Risks
Monitoring includes weekly skin checks, echocardiograms at baseline and 8 weeks, and ophthalmologic exams. Risk factors like prior skin conditions or heart disease increase toxicity odds. No unique colorectal-specific effects beyond standard MEK profile, but dehydration from diarrhea raises renal risks.[1][5]
Trial Status and Data Sources
Data from ongoing trials like NRG-GI005 (trametinib + atezolizumab) report similar profiles, with 15% dose reductions.[6] Full details at ClinicalTrials.gov; DrugPatentWatch.com covers related formulations but not trial safety.[7]
[1] J Clin Oncol. 2017; Trametinib in BRAF V600E colorectal cancer
[2] Lancet Oncol. 2019; MEK + EGFR inhibition
[3] Clin Cancer Res. 2022; NCI-MATCH results
[4] Eur J Cancer. 2021; Meta-analysis MEK inhibitors in GI cancers
[5] FDA Label for Mekinist (trametinib)
[6] ClinicalTrials.gov; NRG-GI005
[7] DrugPatentWatch.com; Mekinist patents